Loading clinical trials...

Stress, Diurnal Cortisol, and Breast Cancer Survival | Clinical Trials | Clareo Health

COMPLETED

Stress, Diurnal Cortisol, and Breast Cancer Survival

NCT00226967•Stanford University

Summary

The purpose of this study is to learn about the effects of stress on hormones, the relationship between these hormones and cancer progression.

Detailed Description

The purpose of this study is to investigate stress and tonic activation of diurnal cortisol in aging metastatic breast cancer patients; feedback inhibition \& activation of cortisol; and stress-induced phasic activation of cortisol.

Eligibility

Age

35 - No limit years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•1. Diagnosis of recurrent or metastatic breast cancer.
•2. Karnofsky of 70% or greater.
•3. Proficient enough in English to be able to take questionnaires and participate in the required tasks.
•4. Living within the Greater Bay Area.
•5. Age 35 or older .

Exclusion Criteria

•1. Positive supraclavicular lymph nodes as the only metastatic lesion at the time of initial diagnosis.
•2. Active cancers within the past 10 years other than breast cancer, basal cell or squamous cell carcinomas of the skin, or in situ cancer of the cervix.
•3. Any other serious medical condition that will effect short term survival
•4. History of major psychiatric illness for which patient was hospitalized or medicated, with the exception of depression or anxiety
•5. A diagnosis of diabetes.

Locations (1)

Stanford University School of Medicine

Stanford, California, United States

Key Dates

Start Date

September 8, 2002

Primary Completion Date

November 1, 2004

Completion Date

December 1, 2005

Last Updated

January 27, 2020

Enrollment

115

ESTIMATED participants

Conditions

Breast Cancer

Interventions

Sandostatin

DRUG

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

NCT05372640

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+6 more

View study

RECRUITINGPHASE1

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

NCT05673200

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+2 more

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 27, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Stress, Diurnal Cortisol, and Breast Cancer Survival

Inclusion Criteria

Exclusion Criteria

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer